Login to Your Account

Clinic Roundup

Thursday, January 12, 2012
• Pharmos Corp., of Iselin, N.J., said the first U.S. patients have been dosed with its levotofisopam (S-tofisopam) in a Phase IIa proof-of-concept trial in hyperuricemia and gout. In two Phase I studies, completed by Vela Pharmaceuticals, which merged with Pharmos in 2006, levotofisopam was generally well tolerated and was associated with a large, rapid reduction in serum uric acid values.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription